India unveils $1.32B PRIP push to tackle rare diseases and drive IP-led growth
In a strategic push to transform India’s pharmaceutical and biotech landscape, the government recently outlined and invited applications for the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, aimed at bolstering R&D capabilities, particularly in rare disease therapies, gene-based treatments, and precision medicine.
The Indian government has now extended the application deadline for the $600 million PRIP Scheme to November 10, 2025, reports The Pharma Letter’s India correspondent.
Ensuring a critical opportunity for pharmaceutical industry leaders in India to align with the country’s innovation-first agenda, PRIP is part of a broader national policy to shift India’s pharma sector from a generics-driven model to an innovation-led ecosystem.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze